Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577339 | 0.85 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNAL3MBTL1GAAADRB3 | |
| SCHEMBL14375039 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNAL3MBTL1GAACFTR | |
| SCHEMBL14878508 | 0.83 | RIPK1 (0.47) | LMNAL3MBTL1 | |
| SCHEMBL1154991 | 0.83 | RIPK1 (0.47) | LMNAL3MBTL1 | |
| SCHEMBL11972243 | 0.81 | ADRB2 (0.38) | ADRB3ADRB1CYP17A1 | |
| SCHEMBL1495415 | 0.79 | GRIN1 (0.35) | LMNA | |
| SCHEMBL26121068 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAL3MBTL1GAAADRB3 | |
| SCHEMBL25207293 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAL3MBTL1GAAADRB3 | |
| SCHEMBL29713534 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAL3MBTL1GAAADRB3 | |
| SCHEMBL507379 | 0.77 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAL3MBTL1GAAADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |